Financing to be conducted by bookrunners UBS, BMO Capital, RBC Capital
By Devika Patel
Knoxville, Tenn., July 23 – Neos Therapeutics, Inc. said it priced its $72 million initial public sale of stock with a $10.8 million greenshoe. The deal was announced June 19.
The company will sell 4.8 million common shares at $15.00 apiece.
UBS Investment Bank, BMO Capital Markets and RBC Capital Markets are the bookrunning managers.
Settlement is expected July 28.
Proceeds will be used for pre-commercialization planning, commercialization, working capital, capital expenditures and general corporate purposes.
The pharmaceutical company is based in Grand Prairie, Texas. The company intends to list its common stock on the Nasdaq under the symbol “NEOS.”
| Issuer: | Neos Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $72 million
|
| Greenshoe: | $10.8 million, or 720,000 shares
|
| Shares: | 4.8 million
|
| Price: | $15.00
|
| Warrants: | No
|
| Bookrunners: | UBS Investment Bank, BMO Capital Markets and RBC Capital Markets
|
| Lead manager: | JMP Securities
|
| Announcement date: | June 19
|
| Pricing date: | July 23
|
| Settlement date: | July 28
|
| Stock exchange: | Nasdaq: NEOS
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
